@article{50821bc3e4be437087a47f8dc456c056,
title = "Generating evidence for therapeutic effects: The need for well-conducted randomized trials",
author = "Califf, {Robert M.} and Curtis, {Lesley H.} and Harrington, {Robert A.} and Hernandez, {Adrian F.} and Peterson, {Eric D.}",
note = "Funding Information: Conflict of interest: RMC is an employee of Verily Life Sciences and Google (both Alphabet companies) and serves on the board of Cytokinetics. RAH has received consulting fees from Bridgebio and holds equity in Element Science. He also receives personal compensation for serving on the board of directors for SignalPath. AFH receives personal fees from Amgen, AstraZeneca, Bayer, Cytokinetics, and Merck, and grants from AstraZeneca and Novartis. EDP has received research support from Amgen, Janssen, Esperion, Bristol Myers Squibb, Sanofi, AstraZeneca, and Merck. He also receives consulting fees from Amgen, Janssen, Novartis, Boehringer Ingelheim, AstraZeneca, Amerin, Sanofi, Abiomed, Merck, Livongo, Cerner, and Eko, and has ownership in Swift Clinical Sciences LLC. Copyright: {\textcopyright} 2021, American Society for Clinical Investigation. Reference information: J Clin Invest. 2021;131(2):e146391. https://doi.org/10.1172/JCI146391.",
year = "2021",
month = jan,
day = "19",
doi = "10.1172/JCI146391",
language = "English (US)",
volume = "131",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",
}